Ocena skuteczności i bezpieczeństwa chemioterapii HLX10 + (karboplatyna-etopozyd) u pacjentów ze Stanów Zjednoczonych z ES-SCLC
Randomizowane, otwarte badanie chemioterapii HLX10 Plus (karboplatyna-etopozyd) w porównaniu z chemioterapią atezolizumabem plus u wcześniej nieleczonych pacjentów ze Stanów Zjednoczonych z rozległym stadium drobnokomórkowego raka płuca (ES-SCLC)
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35223
- Alabama Oncology
-
-
Arizona
-
Goodyear, Arizona, Stany Zjednoczone, 85338
- City of Hope - Phoenix
-
Tucson, Arizona, Stany Zjednoczone, 85715
- Arizona Clinical Research Center (ACRC)
-
-
Arkansas
-
Springdale, Arkansas, Stany Zjednoczone, 72762
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, Stany Zjednoczone, 92708
- Compassionate Care Research Group
-
Fullerton, California, Stany Zjednoczone, 92835
- Providence Medical Foundation
-
Glendale, California, Stany Zjednoczone, 91204
- Los Angeles Cancer Network
-
Los Alamitos, California, Stany Zjednoczone, 90720
- OPN - Oncology Physician Network
-
Los Angeles, California, Stany Zjednoczone, 90034
- Kaiser Permanente Research (Southern California)
-
Sacramento, California, Stany Zjednoczone, 95817
- UC Davis
-
-
Colorado
-
Colorado Springs, Colorado, Stany Zjednoczone, 80920
- UCHealth Memorial Hospital North
-
Greeley, Colorado, Stany Zjednoczone, 80631
- MD Anderson- North Colorado Medical Center
-
-
Florida
-
Brooksville, Florida, Stany Zjednoczone, 34613
- Advanced Cancer Treatment Centers
-
Jacksonville, Florida, Stany Zjednoczone, 32256
- Cancer Specialists North Florida
-
Miami, Florida, Stany Zjednoczone, 33140
- Mount Sinai Comprehensive Cancer Center
-
Ocala, Florida, Stany Zjednoczone, 34473
- Florida Cancer Affiliates- (Ocala Oncology - Main)
-
Orange City, Florida, Stany Zjednoczone, 32763
- Mid Florida Hematology and Oncology Center
-
Plantation, Florida, Stany Zjednoczone, 33322
- BRCR Global
-
Pompano Beach, Florida, Stany Zjednoczone, 33064
- Napa Research
-
Tamarac, Florida, Stany Zjednoczone, 33321
- Advanced Research
-
-
Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96814
- Straub Benioff Medical Center
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60099
- City of Hope- Chicago
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Center of Decatur
-
Tinley Park, Illinois, Stany Zjednoczone, 60487
- Accellacare of Duly
-
-
Indiana
-
Dyer, Indiana, Stany Zjednoczone, 46311
- Northwest Cancer Centers
-
-
Kansas
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40503
- Baptist Health Lexington
-
Pikeville, Kentucky, Stany Zjednoczone, 41501
- Pikeville Hospital
-
-
Louisiana
-
Alexandria, Louisiana, Stany Zjednoczone, 71301
- CHRISTUS St. Frances Cabrini Cancer Center
-
Hammond, Louisiana, Stany Zjednoczone, 70433
- Pontchartrain Cancer Center
-
-
Michigan
-
Southfield, Michigan, Stany Zjednoczone, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Health Partners Cancer Center at Regions Hospital
-
-
Mississippi
-
Hattiesburg, Mississippi, Stany Zjednoczone, 39401
- Hattiesburg Clinic Hematology/Oncology
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64132
- MidAmerica Division Inc., c/o Research Medical Center
-
Osage Beach, Missouri, Stany Zjednoczone, 65065
- Lake Regional
-
-
Montana
-
Billings, Montana, Stany Zjednoczone, 59102
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68106
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Stany Zjednoczone, 89502
- Renown Health
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Freehold, New Jersey, Stany Zjednoczone, 03756
- Regional Cancer Care Associates LLC RCCA
-
Neptune City, New Jersey, Stany Zjednoczone, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Elmhurst, New York, Stany Zjednoczone, 11373
- Elmhurst (BRANY site)
-
Lake Success, New York, Stany Zjednoczone, 11042
- Northwell Health
-
Stony Brook, New York, Stany Zjednoczone, 11794
- Stony Brook Cancer Center
-
Williamsville, New York, Stany Zjednoczone, 14221
- Great Lakes Cancer Care (Kaleida Health)
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44304
- Summa Health
-
Canton, Ohio, Stany Zjednoczone, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, Stany Zjednoczone, 44710
- Aultman Cancer Center
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- University Hospitals Cleveland Medical Center
-
Massillon, Ohio, Stany Zjednoczone, 44646
- Tricounty Hematology and Oncology Associates
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, Stany Zjednoczone, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02908
- CharterCARE (Roger Williams)
-
-
Texas
-
Corpus Christi, Texas, Stany Zjednoczone, 78404
- CHRISTUS Institute for Innovation & Advanced Clinical Care
-
Edinburg, Texas, Stany Zjednoczone, 78539
- DHR Research
-
Houston, Texas, Stany Zjednoczone, 77090
- Millennium Research and Clinical Development
-
Kingwood, Texas, Stany Zjednoczone, 77339
- Lumi Research
-
Lubbock, Texas, Stany Zjednoczone, 79410
- Joe Arrington Cancer Research and Treatment Center
-
Tyler, Texas, Stany Zjednoczone, 75701
- The University of Texas Health Science Center at Tyler/HOPE Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84106
- Utah Cancer Specialists
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Olympia, Washington, Stany Zjednoczone, 98502
- American Oncology Network Vista Oncology Division
-
Tacoma, Washington, Stany Zjednoczone, 98405
- Northwest Medical Specialties, PLLC
-
-
West Virginia
-
Morgantown, West Virginia, Stany Zjednoczone, 26505
- West Virginia University Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Froedtert Hospital- Medical College of Wisconsin
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Voluntary participation in clinical studies.
Male or female aged ≥ 18 years at the time of signing the ICF.
Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).
No prior systemic therapy for ES-SCLC.
Patients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
At least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.
Every effort should be made to provide tumor tissues for the determination of PD-L1 expression.
Prior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
An ECOG PS score of 0 or 1.
An expected survival ≥ 12 weeks.
Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.
Normal major organ functions.
Female patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
Male patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
Exclusion Criteria:
Histologically or cytologically confirmed mixed SCLC.
Other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
Patients who are preparing for or have received an organ or bone marrow transplant.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
Patients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
Subjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
Patients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.
Class III to IV cardiac insufficiency according to NYHA classification.
Subject has uncontrolled or symptomatic hypercalcemia.
Subject with peripheral neuropathy ≥ Grade 2 by CTCAE.
Human immunodeficiency virus (HIV) infection, positive test for HIV antibody.
Active or latent pulmonary tuberculosis.
Subjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
Hepatitis B or Hepatitis C or Hepatitis B and C co-infection.
Known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
Have received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
Subjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
With any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
Major surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
Radical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
The subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
Participation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
Known history of severe allergy to any monoclonal antibody.
Known hypersensitivity to carboplatin or etoposide.
Pregnant or lactating females.
Active use of psychotropics abuse or drug abuse.
In the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Serplulimab + chemotherapy
Serplulimab + chemotherapy (carboplatin-etoposide) |
Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics |
|
Aktywny komparator: Atezolizumab + chemotherapy
Atezolizumab + chemotherapy (carboplatin-etoposide) |
Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
OS
Ramy czasowe: A period from randomization through death regardless of causality (approximately up to 24 months).
|
Overall assessment |
A period from randomization through death regardless of causality (approximately up to 24 months).
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective response rate (ORR)
Ramy czasowe: approximately up to 14 months
|
Objective response rate (ORR) (assessed by independent radiology review committee [IRRC] and the investigator based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) |
approximately up to 14 months
|
|
Progression-free survival (PFS)
Ramy czasowe: approximately up to 24 months
|
Progression-free survival (PFS) (assessed by IRRC and the investigator based on RECIST 1.1) |
approximately up to 24 months
|
|
PFS2
Ramy czasowe: Approximately up to 24 months
|
PFS2 (assessed by the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Duration of response (DOR)
Ramy czasowe: Approximately up to 24 months
|
Duration of response (DOR) (assessed by IRRC and the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Adverse events
Ramy czasowe: approximately up to 24 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. |
approximately up to 24 months
|
|
Observed concentration of HLX10 in serum
Ramy czasowe: Approximately up to 24 months
|
Observed concentration of HLX10 in serum |
Approximately up to 24 months
|
|
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
Ramy czasowe: Approximately up to 24 months
|
The PK data obtained in this study will be pooled with other data from HLX10 (Serplulimab) clinical trials for further population pharmacokinetic analyses. The differences in PK exposure between American population and the obtained populations (Asian and non-Asian) will be compared through model simulation. |
Approximately up to 24 months
|
|
HLX10 anti-drug antibody (ADA)
Ramy czasowe: Approximately up to 24 months
|
HLX10 anti-drug antibody (ADA) |
Approximately up to 24 months
|
|
Neutralizing antibody (NAb)
Ramy czasowe: Approximately up to 24 months
|
Neutralizing antibody (NAb) positive rate |
Approximately up to 24 months
|
|
Quality of life assessment
Ramy czasowe: Approximately up to 24 months
|
Lung cancer Quality of life assessment |
Approximately up to 24 months
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Exploratory Endpoint
Ramy czasowe: Approximately up to 24 months
|
Potential prognostic and predictive biomarkers, including PD-L1 expression in tumor tissue and SCLC-related blood biomarker |
Approximately up to 24 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- ASTRIDE (HLX10-005-SCLC301-E)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .